Cholesterol embolization syndrome and intra-abdominal bleeding immediately after initiation of hemodialysis: a case report with literature review

Abstract Background Cholesterol embolization syndrome (CES) is a disease associating with the systemic cholesterol crystal embolism and end-organ dysfunction due to the atherosclerotic plaque rupture, which is dominantly triggered by the intravascular intervention. There is no consensus for which ty...

Full description

Saved in:
Bibliographic Details
Published inRenal replacement therapy Vol. 6; no. 1; p. 53
Main Authors Kakeshita, Kota, Koike, Tsutomu, Imamura, Teruhiko, Arisawa, Yu, Murai, Sayaka, Shimizu, Ayako, Kiyosawa, Taigo, Yamazaki, Hidenori, Kinugawa, Koichiro
Format Journal Article
LanguageEnglish
Published London Springer Nature B.V 01.12.2020
Subjects
Abdomen
Antibodies
Anticoagulants
Aortic aneurysms
Blood
Case reports
Cholesterol
Coronary vessels
Creatinine
Diabetes
Embolisms
Embolization
Hemodialysis
Hemoglobin
Hypertension
Intervention
Ischemia
Kidney diseases
Laboratories
Lipoproteins
Molecular weight
Patients
Proteins
Steroids
Tomography
Urine
Veins & arteries
Japan
Online AccessGet full text

Cover

More Information
Summary:Abstract Background Cholesterol embolization syndrome (CES) is a disease associating with the systemic cholesterol crystal embolism and end-organ dysfunction due to the atherosclerotic plaque rupture, which is dominantly triggered by the intravascular intervention. There is no consensus for which types of anticoagulants we should use during the hemodialysis in patients with CES and end-stage renal disease. Case presentation We had a 68-year-old man with CES due to intravascular intervention, who suffered the omental bleeding, instead of the embolism, immediately after the initiation of hemodialysis with heparinization. An emergent laparotomy found active bleeding from the omentum, which was surgically repaired. The histopathological analysis showed the embolization of cholesterol crystal clefts in the omentum artery and the injury of arterial wall structure accompanied by the infiltration of inflammatory cells. We preferred nafamostat mesylate during hemodialysis and he had no adverse events following the surgery. Conclusions It should be noticed that, in addition to the embolic events, bleeding events can develop in patients with CES, particularly following the initiation of hemodialysis with anticoagulation therapy.
ISSN:2059-1381
2059-1381
DOI:10.1186/s41100-020-00305-9